关于局部用鲁索替尼治疗白癜风的综述。

A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo.

出版信息

J Drugs Dermatol. 2023 Jul 1;22(7):664-667. doi: 10.36849/JDD.7268.

Abstract

BACKGROUND

This article describes the clinical trial, safety, and efficacy of ruxolitinib 1.5% cream or repigmentation in patients with vitiligo.

DATA SOURCES

A systematic review was done using ruxolitinib or Opzelura in MEDLINE (PubMed) and EMBASE.

CLINICALTRIALS

gov was used to identify ongoing or unpublished studies.

STUDY SELECTION AND DATA EXTRACTION

Studies included were written in English and relevant to pharmacology, clinical trials, safety, and efficacy.

DATA SYNTHESIS

In two 52-week phase 3 trials, 52.0% of subjects had at least 75% improvement in their Facial Vitiligo Area Scoring Index (F-VASI).

RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE

Ruxolitinib is a topical Janus kinase (JAK) inhibitor newly approved by the US Food and Drug Administration for repigmentation in patients with vitiligo.

CONCLUSION

Topical ruxolitinib is the first medication approved for repigmentation in patients with vitiligo. It is a safe and effective treatment; however, cost may be a barrier to some patients when prescribing this medication. Trials to compare the efficacy and side effect profile of topical ruxolitinib with other topical treatments are still needed. Grossmann MC, Haidari W, Feldman SR. A Review on the use of topical ruxolitinib for the treatment of vitiligo. J Drugs Dermatol. 2023;22(7):664-667. doi:10.36849/JDD.7268.

摘要

背景

本文描述了鲁索替尼乳膏或复色在白癜风患者中的临床试验、安全性和疗效。

资料来源

使用 MEDLINE（PubMed）和 EMBASE 中的鲁索替尼或 Opzelura 进行系统评价。

临床试验

gov 用于确定正在进行或未发表的研究。

研究选择和数据提取

选择的研究为英文，与药理学、临床试验、安全性和疗效相关。

数据综合

在两项为期 52 周的 3 期试验中，52.0%的受试者面部白癜风面积评分指数（F-VASI）至少改善了 75%。

与患者护理和临床实践的相关性

鲁索替尼是美国食品和药物管理局新批准的一种局部 Janus 激酶（JAK）抑制剂，用于白癜风患者的复色。

结论

局部鲁索替尼是第一种批准用于白癜风患者复色的药物。它是一种安全有效的治疗方法；然而，对于一些患者来说，开这种药的费用可能是一个障碍。仍需要进行试验来比较局部鲁索替尼与其他局部治疗方法的疗效和副作用特征。Grossmann MC, Haidari W, Feldman SR. A Review on the use of topical ruxolitinib for the treatment of vitiligo. J Drugs Dermatol. 2023;22(7):664-667. doi:10.36849/JDD.7268.